人源化抗肾上腺髓质素抗体Adrecizumab(HAM8101)对啮齿类全身炎症与脓毒症模型血管屏障功能及生存的影响
该研究在啮齿类全身炎症与脓毒症模型中评估人源化抗肾上腺髓质素抗体HAM8101(Adrecizumab)对血管屏障功能及生存的影响。大鼠脂多糖造模后,0.1与2.5 mg/kg HAM8101减轻肾白蛋白渗漏;小鼠盲肠结扎穿刺造模后,0.1、2.0、20 mg/kg HAM8101降低肾白蛋白与VEGF浓度、升高血管生成素-1。单次与重复给予HAM1101及HAM8101均改善小鼠脓毒症生存。结论为预处理HAM8101可改善血管屏障功能与生存,均为动物模型结果。
要点
- 在脂多糖诱导内毒素血症大鼠中,0.1与2.5 mg/kg HAM8101预处理减轻肾白蛋白渗漏。
- 在盲肠结扎穿刺脓毒症小鼠中,0.1、2.0、20 mg/kg HAM8101降低肾白蛋白与VEGF浓度、升高血管生成素-1。
- 单次与重复给予HAM1101及HAM8101均改善盲肠结扎穿刺小鼠脓毒症生存。
- 所有结果均来自啮齿类模型,给药为造模前预处理,非脓毒症确诊后的治疗性给药。
适用人群与场景
- 脂多糖(5 mg/kg)诱导全身炎症的大鼠(n=48,每组8只)。
- 盲肠结扎穿刺(CLP)诱导脓毒症的小鼠(血管渗漏分析n=24,每组6只;生存分析n=60,每组10只)。
- 给药时机为造模前预处理(大鼠在脂多糖给药后直接给药,小鼠在CLP后立即给药)。
处置流程与药物剂量
- 大鼠:给予0.1或2.5 mg/kg HAM8101或安慰剂,随后立即给予脂多糖5 mg/kg,24小时后用伊文思蓝染料评估肾与肝组织血管渗漏。
- 小鼠:给予0.1、2.0或20 mg/kg HAM8101或安慰剂,随后立即行盲肠结扎穿刺,18小时后检测肾组织白蛋白、VEGF与血管生成素-1。
- 生存分析:单次与重复给予HAM1101、HAM8101及安慰剂,在CLP诱导小鼠脓毒症中评估生存(n=60,每组10只)。
研究设计与关键结果
- 研究类型为啮齿类动物实验;大鼠n=48(每组8只)接受不同剂量HAM8101或安慰剂后给予脂多糖5 mg/kg,24小时后评估肾与肝伊文思蓝渗漏。
- 小鼠n=24(每组6只)接受不同剂量HAM8101或安慰剂后立即行CLP,18小时后分析肾组织白蛋白、VEGF与血管生成素-1。
- 0.1与2.5 mg/kg HAM8101减轻内毒素血症大鼠肾白蛋白渗漏。
- 0.1、2.0与20 mg/kg HAM8101降低脓毒症小鼠肾白蛋白与VEGF浓度,同时升高保护性蛋白血管生成素-1浓度。
- CLP诱导小鼠脓毒症生存分析(n=60,每组10只)中,HAM1101与HAM8101单次及重复给药均改善生存。
证据类型、等级与局限
- 证据类型:啮齿类动物实验(大鼠内毒素血症模型与小鼠CLP脓毒症模型)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 原文结论为预处理人源化抗ADM抗体HAM8101改善啮齿类全身炎症与脓毒症模型的血管屏障功能与生存,尚属动物实验阶段。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
PURPOSE: Adrenomedullin (ADM) is an important regulator of endothelial barrier function during sepsis. Administration of a murine antibody targeted against the N-terminus of ADM (HAM1101) resulted in improved outcome in models of murine sepsis. We studied the effects of a humanized form of this antibody (HAM8101, also known as Adrecizumab) on vascular barrier dysfunction and survival in rodent models of systemic inflammation and sepsis.
METHODS: Rats (n=48) received different dosages of HAM8101 or placebo (n = 8 per group), directly followed by administration of lipopolysaccharide (5 mg/kg). Twenty-four hours later, Evans Blue dye was administered to assess vascular leakage in kidney and liver tissue. Furthermore, mice (n = 24) were administered different dosages of HAM8101 or placebo (n = 6 per group), immediately followed by cecal ligation and puncture (CLP). Eighteen hours later, albumin, vascular endothelial growth factor (VEGF), and angiopoietin-1 were analyzed in the kidney. Finally, effects of single and repeated dose administration of HAM1101, HAM8101 and placebo on survival were assessed in CLP-induced murine sepsis (n = 60, n = 10 per group).
RESULTS: Dosages of 0.1 and 2.5 mg/kg HAM8101 attenuated renal albumin leakage in endotoxemic rats. Dosages of 0.1, 2.0, and 20 mg/kg HAM8101 reduced renal concentrations of albumin and the detrimental protein VEGF in septic mice, whereas concentrations of the protective protein angiopoietin-1 were augmented. Both single and repeated administration of both HAM1101 and HAM8101 resulted in improved survival during murine sepsis.
CONCLUSIONS: Pretreatment with the humanized anti-ADM antibody HAM8101 improved vascular barrier function and survival in rodent models of systemic inflammation and sepsis.
参考来源
- Geven C, Peters E, Schroedter M, et al. Effects of the Humanized Anti-Adrenomedullin Antibody Adrecizumab (HAM8101) on Vascular Barrier Function and Survival in Rodent Models of Systemic Inflammation and Sepsis. Shock. 2018. PMID: 29324627. doi:10.1097/SHK.0000000000001102
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。